Yan Marie, Hernandez Alejandro, Chan Kelvin K, Stanbrook Matthew B, Blanchette Phillip S, Johnston James C, Lee Samantha M, Macdonald Liane, Richard-Greenblatt Melissa, Marras Theodore K, Brode Sarah K
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Clin Infect Dis. 2025 Aug 1;81(1):176-178. doi: 10.1093/cid/ciae626.
In this population-based study, we examined the risk of nontuberculous mycobacterial disease associated with immune checkpoint inhibitors among people with cancer. Using a nested case-control design, we identified 184 cases and 714 matched controls; there was no significant association on conditional logistic regression (adjusted odds ratio, 0.51 [95% confidence interval, .17-1.50]; P = .22).
在这项基于人群的研究中，我们调查了癌症患者中与免疫检查点抑制剂相关的非结核分枝杆菌病风险。采用巢式病例对照设计，我们确定了184例病例和714例匹配对照；条件逻辑回归分析显示无显著关联（调整优势比为0.51[95%置信区间为0.17 - 1.50]；P = 0.22）。
